Serum IgM reactivities of patients with IPAH, SSc with or without PAH, and healthy individuals with endothelial cell antigens
| Patient groups/antigen sources | HUVEC | HMVEC-d | HMVEC-l |
|---|---|---|---|
| For definition of abbreviations see footnote to table 2. | |||
| Healthy individuals | |||
| No of reactivity peaks | 4–6 | 11–13 | 9–11 |
| Main reactivities (no of individuals) | 55 kDa (25/65) | 38 kDa (41/65) | 32 kDa (50/65) |
| 63 kDa (37/65) | 55 kDa (65/65) | 48 kDa (55/65 | |
| 90 kDa (25/65) | 65 kDa (65/65)) | ||
| 90 kDa (30/65) | |||
| IPAH | |||
| No of reactivity peaks | 4–6 | 8–10 | 10–12 |
| Main reactivities (no of patients) | 55 kDa (14/35) | 38 kDa (25/35) | 32 kDa (20/35) |
| 63 kDa (18/35) | 50 kDa (24/35) | 48 kDa (32/35) | |
| 55 kDa (35/35) | 57 kDa (28/35) | ||
| 63 kDa (13/35) | 65 kDa (35/35) | ||
| 90 kDa (16/35) | 90 kDa (10/35 | ||
| SSc with PAH | |||
| No of reactivity peaks | 4–6 | 8–10 | 8–10 |
| Main reactivities (no of patients) | 55 kDa (4/10) | 27 kDa (5/10) | 32 kDa (8/10) |
| 63 kDa (5/10) | 38 kDa (9/10) | 48 kDa (8/10) | |
| 55 kDa (10/10) | 57 kDa (5/10) | ||
| 65 kDa (9/10) | |||
| Limited cutaneous SSc without PAH | |||
| No of reactivity peaks | 4–6 | 9–11 | 8–12 |
| Main reactivities (no of patients) | 55 kDa (7/10) | 38 kDa (10/10) | 32 kDa (8/10) |
| 63 kDa (8/10) | 55 kDa (10/10) | 48 kDa (10/10) | |
| 90 kDa (10/10) | 65 kDa (9/10) | ||
| Diffuse SSc without PAH | |||
| No of reactivity peaks | 4–6 | 9–11 | 10–12 |
| Main reactivities (no of patients) | 55 kDa (8/10) | 38 kDa (5/10) | 32 kDa (5/10) |
| 63 kDa (6/10) | 55 kDa (10/10) | 48 kDa (9/10) | |
| 80 kDa (5/10) | 65 kDa (1010) | ||
| 90 kDa (5/10) | |||